We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer
Read MoreHide Full Article
Key Takeaways
RVMD shares fell 17% after a WSJ report said MRK withdrew from buyout talks following a price impasse.
The WSJ report said discussions between MRK and RVMD could resume, or another bidder could step in.
RVMD is advancing daraxonrasib, with phase III PDAC data and other phase III studies expected this year.
Shares of Revolution Medicines (RVMD - Free Report) slipped 17% yesterday after a Wall Street Journal (WSJ) report said, quoting people familiar with the matter, that pharma bigwig Merck (MRK - Free Report) was no longer pursuing the acquisition of this California-based clinical-stage cancer biotech.
The article mentioned that the buyout talks hit a roadblock after Revolution Medicines and Merck could not align over the buyout price. The report also confirmed that buyout talks between MRK and RVMD could soon resume, or that a new bidder for the latter could eventually make the headlines.
Reportedly, both companies have declined to comment on the latest turn of events.
The latest WSJ report comes on the heels of a recent Financial Times report, which stated that Merck was in talks to buy Revolution Medicines for up to $32 billion. The report, however, mentioned that the companies were yet to finalize the deal. Some other large drugmakers have also been pursuing the acquisition of RVMD, and a valuation range of approximately $28 billion to $32 billion has been under consideration.
Revolution Medicines is engaged in developing novel drugs that target the active, GTP-bound form (or ON form) of RAS proteins, which the company refers to as RAS(ON). A potential buyout of RVMD would have boosted Merck’s oncology pipeline.
In the past six months, shares of Revolution Medicines have soared 162.4% compared with the industry’s rise of 21.6%.
Image Source: Zacks Investment Research
RVMD's Oncology Pipeline Progressing Well
Revolution Medicines’ lead pipeline candidate, daraxonrasib, is an investigational oral RAS(ON) multi-selective inhibitor designed to target several forms of RAS mutations.
Daraxonrasib is being evaluated in late-stage studies for treating patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The company expects data readout from a phase III PDAC study later in 2026, while phase III studies in first-line metastatic PDAC and NSCLC are also expected to begin later this year.
RVMD is also developing mutant-selective inhibitors like elironrasib and zoldonrasib that are designed to suppress the growth of specific RAS-bearing cancer cells. Both drugs are being evaluated either as monotherapy or in combination with other anti-cancer therapies in separate early-stage studies across solid tumor indications.
While first-generation RAS inhibitors, such as Amgen’s Lumakras and Bristol-Myers’ Krazati, are available on the market, they are not designed to address the resistance mechanisms that limit their long-term efficacy. Notably, Revolution Medicines’ RAS(ON) inhibitors are specifically designed to overcome these resistance barriers, potentially offering more durable clinical responses.
Over the past 60 days, estimates for Alkermes’ 2026 earnings per share have increased from $1.54 to $1.91. Shares of ALKS have gained 26.6% over the past six months.
Alkermes’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 4.58%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer
Key Takeaways
Shares of Revolution Medicines (RVMD - Free Report) slipped 17% yesterday after a Wall Street Journal (WSJ) report said, quoting people familiar with the matter, that pharma bigwig Merck (MRK - Free Report) was no longer pursuing the acquisition of this California-based clinical-stage cancer biotech.
The article mentioned that the buyout talks hit a roadblock after Revolution Medicines and Merck could not align over the buyout price. The report also confirmed that buyout talks between MRK and RVMD could soon resume, or that a new bidder for the latter could eventually make the headlines.
Reportedly, both companies have declined to comment on the latest turn of events.
The latest WSJ report comes on the heels of a recent Financial Times report, which stated that Merck was in talks to buy Revolution Medicines for up to $32 billion. The report, however, mentioned that the companies were yet to finalize the deal. Some other large drugmakers have also been pursuing the acquisition of RVMD, and a valuation range of approximately $28 billion to $32 billion has been under consideration.
Revolution Medicines is engaged in developing novel drugs that target the active, GTP-bound form (or ON form) of RAS proteins, which the company refers to as RAS(ON). A potential buyout of RVMD would have boosted Merck’s oncology pipeline.
Earlier this month, a report from the WSJ stated that another large drugmaker, AbbVie (ABBV - Free Report) , was in advanced talks to acquire Revolution Medicines. However, AbbVie denied the rumors in an emailed statement to Reuters.
RVMD's Price Performance
In the past six months, shares of Revolution Medicines have soared 162.4% compared with the industry’s rise of 21.6%.
Image Source: Zacks Investment Research
RVMD's Oncology Pipeline Progressing Well
Revolution Medicines’ lead pipeline candidate, daraxonrasib, is an investigational oral RAS(ON) multi-selective inhibitor designed to target several forms of RAS mutations.
Daraxonrasib is being evaluated in late-stage studies for treating patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The company expects data readout from a phase III PDAC study later in 2026, while phase III studies in first-line metastatic PDAC and NSCLC are also expected to begin later this year.
RVMD is also developing mutant-selective inhibitors like elironrasib and zoldonrasib that are designed to suppress the growth of specific RAS-bearing cancer cells. Both drugs are being evaluated either as monotherapy or in combination with other anti-cancer therapies in separate early-stage studies across solid tumor indications.
While first-generation RAS inhibitors, such as Amgen’s Lumakras and Bristol-Myers’ Krazati, are available on the market, they are not designed to address the resistance mechanisms that limit their long-term efficacy. Notably, Revolution Medicines’ RAS(ON) inhibitors are specifically designed to overcome these resistance barriers, potentially offering more durable clinical responses.
Revolution Medicines, Inc. Price
Revolution Medicines, Inc. price | Revolution Medicines, Inc. Quote
RVMD’s Zacks Rank & Stock to Consider
Revolution Medicines currently has a Zacks Rank #3 (Hold).
A better-ranked stock in the biotech sector is Alkermes (ALKS - Free Report) , sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Alkermes’ 2026 earnings per share have increased from $1.54 to $1.91. Shares of ALKS have gained 26.6% over the past six months.
Alkermes’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 4.58%.